The federal government has now invested about $6 billion in the Covid-19 vaccine from Moderna, the Cambridge, Mass., biotech that few outside the scientific and investment worlds had heard of a couple of years ago.
Moderna said in a filing with the Securities and Exchange Commission on Wednesday that under a change in its government contract on April 18, it will receive as much as $236 million in additional reimbursement for costs associated with its late-stage vaccine trial on about 30,000 volunteers, including safety monitoring.
The additional money is on top of the $5.75 billion that the government already poured into Moderna to help it develop, test, and manufacture the messenger RNA vaccine ― as well as to secure 300 million doses.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect